Bulletin
Investor Alert

New York Markets After Hours

Associated Press Archives | Email alerts

May 26, 2020, 7:45 a.m. EDT

WHO drops hydroxychloroquine from global study of experimental COVID-19 treatments

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Associated Press

LONDON — The World Health Organization said that it will temporarily drop hydroxychloroquine — the malaria drug U.S. President Trump has said he is taking — from its global study into experimental COVID-19 treatments, saying that its experts need to review all available evidence to date.

In a news briefing on Monday, WHO director-general Tedros Adhanom Ghebreyesus said that in light of a paper published last week in the Lancet, that found people taking hydroxychloroquine were at higher risk of death and heart problems than those that were not, there would be “a temporary pause” on the hydroxychloroquine arm of its global clinical trial.

“This concern relates to the use of hydroxychloroquine and chloroquine in COVID-19,” Tedros said, adding that the drugs remain, as has been the case for decades, accepted treatments for people with malaria or autoimmune diseases.

Other treatments in the study, including the experimental drug remdesivir and an HIV combination therapy, are still being pursued.


Getty Images
Packets of a Nivaquine, with tablets containing chloroquine and Plaqueril, whose tablets contain hydroxychloroquine, are shown in February at the Mediterranée infection Institute in Marseille, France.

Read on: Moderna’s stock soars then dips after questions arise around the limited data shared about its COVID-19 vaccine

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.